Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Sexual Dysfunction, Physiological 1Recurrence 1Non Small Cell Lung Cancer Metastatic 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Glioma 1Glioblastoma 1Ganglioneuroblastoma 1Eunuchism 1Erectile Dysfunction 1Diffuse Intrinsic Pontine Glioma 1Astrocytoma 1Advanced Non-Small Cell Lung Cancer 1ALK-positive Non-small Cell Lung Cancer 1ALK Positive Non-small Cell Lung Cancer 1

Interventions

Temozolomide 10Specimen Handling 6Radiotherapy 6Magnetic Resonance Spectroscopy 6pembrolizumab 3Bevacizumab 3trametinib 2Surgical Procedures, Operative 2Radiation 2Magnetic Resonance Imaging 2Leukapheresis 2Genetic Therapy 2Fluorodeoxyglucose F18 2Biopsy 2vorasidenib 1trastuzumab deruxtecan 1ribociclib 1regorafenib 1olutasidenib 1mirdametinib 1lorlatinib 1dabrafenib 1apixaban 1aflibercept 1abexinostat 1Vinblastine 1Tretinoin 1Therapies, Investigational 1Restraint, Physical 1Re-Irradiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Astrocytoma × lorlatinib × Clear all
NCT06333899 2026-03-12

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Nationwide Children's Hospital

Phase EARLY_PHASE1 Recruiting
15 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡